Subscribe
Share
Share
Embed
Barrett esophagus with dysplasia is followed through one patient, a sixty-four-year-old woman whose community biopsy reads high-grade dysplasia. The organizing idea is that every step follows cancer risk and tissue evidence. An expert GI pathologist confirms the reading first, and the grade sets the next step. A slower second endoscopic look comes before treatment because a cancer may be hidden. Anything visible is resected before any ablation, and the depth of the resected lesion decides between endoscopy and surgery. The remaining Barrett is then ablated, usually with radiofrequency ablation, with cryotherapy as salvage. Eradication is not cure, so lifelong twice-daily PPI and intensive early surveillance follow.
Topics covered
Key decisions
This is an AI-generated podcast, and some pronunciations may be imperfect. Thank you for your understanding, and we hope you enjoyed this content.
For the full chapter with MCQs, tables, and primary-guideline references, visit www.boardpearls.com.
Questions or feedback: hello@boardpearls.com.
The most complete gastroenterology board-review podcast on the web, and it is entirely free. This is the GI series from Board Pearls: board review built around clinical reasoning, not recall. Every episode takes one high-yield topic and works it the way you would on rounds: a case to anchor it, the framework that sorts the differential, and the specific decisions the exam rewards. No trivia, no textbook dictation, just the thinking that earns the point.
Over 100 episodes span the full blueprint across nine modules (esophagus, stomach and duodenum, small bowel, colon, pelvic floor, liver, pancreas and biliary, endoscopy, and the cross-cutting topics), grouped by chapter and built from the guidelines and pivotal trials the boards are written from: ACG, AGA, AASLD, and ASGE.
Pair it with the written curriculum, question bank, and AI tutor at boardpearls.com. Questions or feedback: hello@boardpearls.com.
Welcome to Board Pearls. This is episode two of three of the Barrett Esophagus and Esophageal Cancer chapter, in the Esophageal Disorders module. This episode is Barrett esophagus with dysplasia, through one patient. A sixty-four-year-old woman with long-segment Barrett esophagus is followed from a biopsy report of high-grade dysplasia through treatment and the years after. Her case teaches why an expert pathologist reads her slides before anything else, what each grade of dysplasia calls for, why a second, slower endoscopic look comes before treatment, why anything visible is removed before anything is ablated, how the depth of the resected lesion decides between endoscopy and surgery, how the remaining Barrett is ablated, and why clearing the Barrett isn't the end of her care.
Here's the patient. A sixty-four-year-old woman has had long-segment Barrett esophagus, six centimeters, under surveillance for eight years. Her biopsies have always been non-dysplastic. At this surveillance endoscopy, the community pathologist reports high-grade dysplasia in two of the biopsies. The endoscopist didn't see anything unusual. She's healthy and active, and she's frightened, because she's read that the treatment is removing her esophagus.
Her report says high-grade dysplasia in Barrett esophagus. Dysplasia is the pathologist's reading of cellular and architectural abnormality in the Barrett lining that grades her cancer risk: nuclear enlargement, variation in nuclear shape, dark-staining nuclei, stacking of nuclei, atypical mitoses, loss of the cytoplasm's normal maturation, and crowding of glands. Low-grade dysplasia keeps maturation at the surface; high-grade dysplasia loses it. Before anything else, her reading has to be confirmed by an expert gastrointestinal, GI, pathologist, because agreement among general pathologists on dysplasia is poor, especially for low-grade dysplasia. The same slide can be read as non-dysplastic, indefinite, or dysplastic by different readers. When expert GI pathologists reviewed close to three hundred community diagnoses of low-grade dysplasia in one cohort, only about a quarter were confirmed, and most of the rest were reread as non-dysplastic. Treating an unconfirmed reading usually means ablating a disease that isn't there. Her slides go to an expert GI pathologist, who confirms high-grade dysplasia.
Her grade matters because each grade's next step follows its cancer risk. Non-dysplastic Barrett progresses to adenocarcinoma at about two to five tenths of a percent a year. Indefinite for dysplasia means the pathologist can't tell dysplasia from the reactive change of acid injury, so the acid is removed and the lining is looked at again: a twice-daily proton pump inhibitor, PPI, for three to six months, then repeat endoscopy with biopsies. Most indefinite readings resolve to non-dysplastic once the inflammation settles. If the reading is still indefinite, surveillance moves to every twelve months. A patient with mild esophagitis and an indefinite biopsy gets twice-daily PPI and a repeat exam, not ablation.
Confirmed low-grade dysplasia progresses at more than half a percent a year, with most cohorts near one percent, and the more pathologists agree on the reading, the more it behaves like high-grade dysplasia. It's a shared decision between two acceptable paths: endoscopic eradication therapy, or surveillance every twelve months. Eradication is favored when life expectancy is reasonable, because radiofrequency ablation reduces progression to high-grade dysplasia and cancer in randomized trials. Surveillance is acceptable for older patients, those with limited life expectancy, and those who decline ablation after counseling. The first repeat endoscopy is usually at six months on twice-daily PPI, because low-grade dysplasia that disappears on a clean acid-suppressed exam was probably overcalled, and dysplasia that persists across two exams is treated. On the surveillance path, endoscopy is at six and twelve months, then yearly.
High-grade dysplasia, like hers, progresses to cancer at about five to eight percent a year without treatment, with some series quoting up to seven percent and older series reaching ten. And ten to twenty percent of patients with high-grade dysplasia already have a cancer hidden somewhere in the segment when the dysplasia is found. That's why high-grade dysplasia is treated with endoscopic eradication in essentially every patient with reasonable life expectancy, and why the first step is to look again, carefully.
That answers her fear right away. Esophagectomy used to be the treatment for high-grade dysplasia, and it now remains an option only for multifocal high-grade dysplasia with deep submucosal invasion that can't be completely resected endoscopically, or for patients in whom endoscopic therapy fails. Even an eighty-year-old with a six-centimeter segment of expert-confirmed high-grade dysplasia and no visible nodule is treated endoscopically.
The hidden cancer is why her treatment begins with a second look. She's referred to an experienced endoscopist. With high-definition white light and chromoendoscopy, the whole segment is inspected slowly, and four-quadrant biopsies are taken every centimeter, the tighter interval used once dysplasia is known. This time a subtle, slightly raised, eight-millimeter nodule is found at the three o'clock position. It was there before, and it was missed.
The nodule changes the plan, and the rule is resect first, ablate second. Anything visible is removed by endoscopic resection before any ablation. Removing it does two things. It clears the bulk of the neoplastic tissue. And it gives the pathologist a specimen large enough to stage: how deep it invades, whether the lateral and deep margins are clear, and whether there's lymphovascular invasion. Forceps biopsies can't determine depth. Ablating the nodule instead would destroy the staging specimen and could understage a cancer that had already reached the submucosa, which would need surgery. That's why guidelines make resection of any visible nodularity a strong recommendation, and why a patient with a nodule who can't have a resection locally is referred to a tertiary center that can.
Resection also corrects the diagnosis. It changes the histology in a third to a half of patients, and about two thirds of those changes are downgrades.
Endoscopic mucosal resection is the usual technique, and it comes in two methods. In suck-and-cut, the area is lifted with a submucosal saline injection, suctioned into a cap on the scope, and snared. In band-and-cut, an elastic band is placed around the mucosa, as in variceal banding, and the resulting pseudopolyp is snared. It removes lesions up to about one and a half to two centimeters comfortably; larger ones can be removed piecemeal, at some cost to margin assessment.
Endoscopic submucosal dissection uses specialized electrosurgical knives to remove a lesion in one piece with full lateral and deep margins. That single specimen matters for lesions over two centimeters and for lesions that look as though they invade deeper, such as depressed or excavated ones, classified as Paris two c or two a plus c. Its drawbacks are longer procedures, more perforation risk, and a steep learning curve, and American Gastroenterological Association guidance notes that most Barrett lesions are well managed by mucosal resection. Her eight-millimeter raised nodule is removed by mucosal resection.
Her specimen's depth now decides between endoscopy and surgery, because depth predicts lymph node spread. Intramucosal carcinoma, stage T1a, is divided into three levels. M1 is high-grade dysplasia confined to the epithelium. M2 is carcinoma invading the lamina propria but sparing the muscularis mucosae. M3 is carcinoma invading but not penetrating the muscularis mucosae. Node risk is under two percent for m1 and m2, and higher at m3 but still in the single digits. Both are low enough that intramucosal cancer is treated endoscopically in most patients, with resection followed by ablation of the remaining flat segment, and a multidisciplinary review for borderline cases.
Once a cancer invades the submucosa, stage T1b, nodal risk rises sharply with each third of submucosal depth, reaching up to two thirds for the deepest. So submucosal invasion is where surgery enters the discussion. There's one exception: a superficial submucosal cancer, less than five hundred micrometers deep, well or moderately differentiated, without lymphovascular invasion, can be managed endoscopically, especially in a poor surgical candidate. Deeper submucosal invasion goes to esophagectomy.
Her resection shows intramucosal carcinoma at the m2 level, invading the lamina propria but not the muscularis mucosae, with clear margins and no lymphovascular invasion. Her cancer is intramucosal and low risk, so she continues endoscopic treatment.
With the cancer removed and staged, the rest of the Barrett still has to go. The nodule is gone, but the flat Barrett around it is the field that grew it, and it can grow another. So the remaining segment is ablated.
Radiofrequency ablation is the standard method and the preferred ablative therapy in current American College of Gastroenterology guidance. It delivers a controlled thermal injury, about twelve joules per square centimeter in the standard circumferential protocol, that destroys the columnar lining and the tissue just beneath it without injuring the deeper submucosa or muscularis propria. The area then heals as squamous mucosa under acid suppression. A three-hundred-sixty-degree balloon treats circumferential segments, and a focal device, in ninety- or sixty-degree versions, treats residual tongues, islands, and the junction after ablation. Most patients need two to four sessions, two to three months apart, continued until no Barrett remains.
The evidence for ablation is strong. In a sham-controlled trial of patients with dysplastic Barrett, ablation cleared low-grade dysplasia in about ninety percent at one year, with high-grade dysplasia cleared somewhat less often but still in a large majority, and it reduced both progression and cancer compared with sham. Real-world series clear dysplasia in eighty-six to ninety-three percent. Intestinal metaplasia is cleared in seventy-seven to eighty-seven percent, and cancer risk falls about tenfold compared with surveillance alone.
Cryotherapy is the alternative when radiofrequency ablation fails or isn't tolerated, such as with a narrowed esophagus, a stricture from prior ablation, or a very long segment. Spray cryotherapy delivers liquid nitrogen or carbon dioxide through a catheter, and balloon cryotherapy delivers nitrous oxide through a balloon in contact with the lining. Rapid freezing and thawing forms ice crystals inside cells and clots small vessels, and the tissue dies. It clears dysplasia in about ninety-seven percent in published series, and it's generally well tolerated, with less pain afterward and fewer strictures. Argon plasma coagulation, an older thermal method largely replaced by radiofrequency ablation, still treats small residual islands afterward. Photodynamic therapy with porfimer sodium, the first widely used ablation method, is obsolete, because of strictures in up to thirty percent and prolonged photosensitivity.
Twice-daily PPI is essential throughout, starting before the first ablation session and continuing indefinitely, because acid keeps the new squamous lining from regrowing and drives recurrence. Some centers add a histamine two receptor blocker at bedtime during the first weeks after ablation to suppress acid breakthrough at night.
She's warned about the predictable complications before her first session. Stricture is the most common, in about five to six percent of ablations overall, and more often when resection came first, especially a resection covering more than half the circumference; sequential balloon dilation almost always fixes it. Bleeding occurs in about one percent and is managed endoscopically. Perforation is rare, about six tenths of a percent with radiofrequency ablation, somewhat more with submucosal dissection and large resections. Chest pain for several days after ablation is expected, and it's managed with topical anesthetics such as viscous lidocaine, sucralfate, and high-dose acid suppression.
The goal is complete eradication of intestinal metaplasia: no visible Barrett at endoscopy, and no intestinal metaplasia on biopsies of the new squamous lining and the gastroesophageal junction. She reaches it after three ablation sessions.
Eradication isn't cure, and that shapes the rest of her care. Intestinal metaplasia recurs in about nine to ten percent of patients per year of follow-up, mostly at the junction or within one to two centimeters above it, where ablation reaches least and acid exposure keeps favoring columnar regrowth. Recurrent dysplasia or cancer is less common, around two percent per patient-year or less.
So her surveillance after eradication is more intensive than it was before, because the highest yield is in the first year. After high-grade dysplasia or intramucosal cancer, endoscopy is at three, six, and twelve months in the first year, then every year. After low-grade dysplasia, the American College of Gastroenterology advises endoscopy at one and three years, then every two years, while American Gastroenterological Association guidance returns to standard non-dysplastic intervals after the three-year exam. Each exam takes four-quadrant biopsies of the junction and of the distal two to three centimeters of new squamous lining, plus targeted biopsies of anything visible.
The deep biopsies of the new lining also look for buried Barrett, metaplasia hidden under regenerated squamous epithelium. It's a recognized finding after ablation, but uncommon when ablation reached adequate depth, and its clinical importance is debated.
Eradication fails in ten to twenty percent of patients, most often with very long segments, persistent reflux, a narrowed esophagus, or high-grade dysplasia or intramucosal cancer at the start. Then the options are cryotherapy, repeat mucosal resection or submucosal dissection of residual disease, and, in selected patients, esophagectomy. For persistent recurrence at the junction despite optimized acid suppression, antireflux surgery can help control the reflux, though surgery alone isn't advised as cancer prevention.
Here are the traps the boards set in this patient.
At diagnosis, acting on a community dysplasia reading without expert confirmation usually treats a disease that isn't there. Ablating indefinite dysplasia skips the twice-daily PPI and repeat exam that resolve most of these readings. And sending high-grade dysplasia to esophagectomy is outdated when endoscopic eradication is the standard.
During treatment, skipping the careful second look misses the hidden cancer that ten to twenty percent already have. Ablating a visible nodule instead of resecting it first destroys the staging specimen. And treating deep or high-risk submucosal invasion endoscopically leaves node risk untreated, when only the superficial low-risk lesion qualifies.
After treatment, stopping the PPI invites recurrence. And treating eradication as cure, with routine surveillance afterward, misses recurrence at the junction, which is why surveillance after high-grade disease begins at three months.
So, start to finish.
Any dysplasia must be confirmed by an expert GI pathologist. Indefinite readings get twice-daily PPI and a repeat exam. Confirmed low-grade dysplasia gets eradication or yearly surveillance by shared decision.
High-grade dysplasia and intramucosal cancer get endoscopic eradication in nearly everyone. That starts with a careful second look, then resection of anything visible to stage it, then radiofrequency ablation of the remaining Barrett until no intestinal metaplasia remains, with cryotherapy as salvage. Submucosal invasion moves toward surgery, except a superficial, low-risk lesion in a poor candidate.
Twice-daily PPI continues for life. Stricture is the main complication and responds to dilation. After high-grade disease, surveillance is at three, six, and twelve months, then yearly, with biopsies at the junction where recurrence clusters.
Episode three is esophageal cancer that's already established: the two types and their different causes, staging in the right order, and how stage and histology decide between endoscopy, surgery, chemotherapy, and radiation.